BioRegenx, Inc (BRGX) fair value: what the stock is really worth
As of Oct 19, 2026: fair value (intrinsic value) of BioRegenx, Inc stock $0.00, price $0.00, upside +6.0%, quality 37 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
BioRegenx, Inc. engages in the research, development, and commercialization of dietary supplements, medical devices, software, and contactless diagnostic technologies in the United States and internationally.
Show moreShow less
The company offers DocSun AI engine, which integrates with a ballistocardiograph that detects an individual's heartbeat; TruScan.AI mobile app for additional health indications; VitalWellness app for DNA and epigenetics platform; and Endocalyx Pro, a dietary supplement targeting microvascular capillary health.
It also provides MyBodyRx, a supplement; GlycoCheck software and medical devices; hydrogen water products and health and wellness devices, such as pulsed electro-magnetic field devices; StimaWELL and ReLounge electronic muscle stimulation therapy devices; and Findit.com, a social media content management platform.
The company sells its products through a direct selling channel to health professionals and research organizations. BioRegenx, Inc. is headquartered in Chattanooga, Tennessee.
Stock analysis
BioRegenx, Inc (BRGX) currently trades at $0.0040, while our model-based Fair Value estimate is $0.0042, so the stock looks roughly fairly valued today (gap 5.7%).
Show more
Valuation
How firm this estimate is: it rests on 6 models at a data quality of 96/100, which puts the data coverage at low.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
BioRegenx, Inc reported revenue of $1.9M in FY2025 versus $199K in FY2021, a compound +74.8%/yr. Reported net income was −$1.5M in FY2025.
Key figures
Market cap $3.9M Micro · P/S ratio 2.20 · Net margin −83.2% · Return on equity −382% · Return on assets (EBIT) −1,042% · Operating margin −11.7% · Revenue (TTM) $1.8M · Revenue growth (YoY) −17.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 83% below its 52-week high and 33% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 9% fair-value upside, at 6%, BRGX screens richer than that median.
Fair Value models
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.48/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−20.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+253.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.6%
Start year 2020 (pandemic). Over 10 years: +18.4% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.4%
’12
’14
’15
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−53.4% (2020) → −28.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+56.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +52.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 118 stocks
Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score37 · Bottom 25%
Fair Value upside+6.0% · Above median
Profitability
Return on equity (12 months)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Net margin (12 months)−73.8% · Bottom 25%
Operating margin (12 months)−11.7% · Below median
Growth and dividend
Revenue growth (quarter YoY)−17.3% · Bottom 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months)2.20× · Cheaper than median
Price / free cash flow129.6× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)41· sector 0
FUTURE (revenue growth)0· sector 39
PAST (return on equity)0· sector 10
HEALTH (low debt)0· sector 98
DIVIDEND (yield)0· sector 43
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "BioRegenx, Inc Fair Value". https://www.fairvalue-calculator.com/stock/BRGX
Frequently asked questions
Is BioRegenx, Inc (BRGX) overvalued or undervalued?
As of Oct 21, 2026, our model estimates a fair value of $0.0042 versus a price of $0.0040, about +6% upside (fairly valued).
What is the fair value of BRGX?
Our model-based fair value for BioRegenx, Inc is $0.0042 (as of Oct 21, 2026), built from audited fundamentals. The current price: $0.0040.
What is the quality score of BRGX?
BioRegenx, Inc has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioRegenx, Inc (BRGX)?
Our model-based price target is the fair value of $0.0042 (as of Oct 21, 2026) from 2 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the BioRegenx, Inc stock forecast for 2026?
Our models put fair value at $0.0042, about +6% upside versus a price of $0.0040 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of BioRegenx, Inc (BRGX)?
BioRegenx, Inc reported trailing-twelve-month revenue of about $1.8M (latest available figure, as of Oct 21, 2026).
What growth is priced into BioRegenx, Inc (BRGX)?
For today's price to be fair in a discounted-cash-flow model, BioRegenx, Inc would have to grow free cash flow by +56.3 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +35.6 % per year. As of Oct 21, 2026.
What discount rate (WACC) does the fair value of BRGX use?
Our models discount BioRegenx, Inc at 9.7 %: a base by market capitalisation (nano), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BioRegenx, Inc that is +56.3 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has BioRegenx, Inc (BRGX) delivered so far?
Over the past 5 years revenue at BioRegenx, Inc grew +35.6 % a year. The price currently implies +56.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BioRegenx, Inc (BRGX) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into BioRegenx, Inc (+56.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BioRegenx, Inc (BRGX)?
The free-cash-flow yield on the price is 0.77 %: that much free cash flow BioRegenx, Inc produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BioRegenx, Inc (BRGX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioRegenx, Inc it is $0.0042 per share (as of Oct 21, 2026), against a price of $0.0040. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is BioRegenx, Inc stock overvalued or undervalued in 2026?
As of Oct 21, 2026, BRGX trades below its calculated fair value: price $0.0040, fair value $0.0042, a gap of about +6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BRGX?
No. The price is what the market pays today ($0.0040); the fair value is what the company's own numbers justify ($0.0042). For BioRegenx, Inc the two are $0.0002 per share apart. That gap is exactly why we show both numbers side by side.
How much is BioRegenx, Inc worth?
The market values BioRegenx, Inc at about $3.9M (market capitalisation, as of Oct 21, 2026). Per share that is $0.0040; our models calculate a fair value of $0.0042 per share.
How solid is the balance sheet of BioRegenx, Inc (BRGX)?
Balance-sheet figures for BioRegenx, Inc (as of Oct 21, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is BRGX from its 52-week high?
BioRegenx, Inc trades at $0.0040, about 83% below its 52-week high of $0.0240 and 33% above the low of $0.0030 (as of Oct 19, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0042 is for.
Which stocks are comparable to BioRegenx, Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioRegenx, Inc stock attractive at the current price?
The data as of Oct 21, 2026: price $0.0040, calculated fair value $0.0042 (+6%), Quality Score 37/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BRGX calculated?
We run BioRegenx, Inc through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0042, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6 % above its aggregate fair value. BioRegenx, Inc currently trades 6 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioRegenx, Inc (BRGX)?
The closing price on Oct 19, 2026 was $0.0040. Our model-based fair value is $0.0042, about +6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioRegenx, Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of BioRegenx, Inc
How large is the market capitalisation of BioRegenx, Inc (BRGX)?
The market capitalisation of BioRegenx, Inc is $3.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioRegenx, Inc (BRGX)?
The price-to-sales ratio of BioRegenx, Inc is 2.20 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of BioRegenx, Inc (BRGX)?
The net margin of BioRegenx, Inc is −83.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BioRegenx, Inc (BRGX)?
The return on equity (ROE) of BioRegenx, Inc is −382% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioRegenx, Inc (BRGX)?
On an EBIT basis the return on assets of BioRegenx, Inc is −1,042% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioRegenx, Inc (BRGX)?
The operating margin of BioRegenx, Inc is −11.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioRegenx, Inc (BRGX)?
Revenue at BioRegenx, Inc is growing −17.3% versus a year earlier (3y avg +253%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does BioRegenx, Inc (BRGX) carry?
The net debt of BioRegenx, Inc is $2.1M (fiscal year 2025, ≈ 71.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch BioRegenx, Inc in the live analysis
One click puts BioRegenx, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 21, 2026